Abstract:Background OX40/OX40 ligand (OX40/OX40L) and programmed death-1/programmed death ligand-1 (PD-1/PD-L1) costimulatory signals play important roles in T cell-induced immune responses. The aim of this study was to investigate the roles of OX40/OX40L and PD-1/PD-L1 costimulatory pathways in mouse islet allograft rejection.Methods Lentiviral vectors containing OX40L siRNA sequences and an adenovirus vector containing the PD-L1 gene were constructed. The streptozotocin-induced model of diabetes was established in C57BL/6 (H-2(b)) mice. Diabetic C57BL/6 mice were randomly allocated into five groups: group 1, untreated control; group 2, Ad-EGFP treatment; group 3, Ad-PD-L1 treatment; group 4, OX40L-RNAi-LV treatment; group 5, OX40L-RNAi-LV combined with Ad-PD-L1 treatment. Lentiviral vector and the adenovirus vector were injected, singly or combined, into the caudal vein one day before islet transplantation. The islets of DBA/2 (H-2(d)) mice were transplanted into the renal subcapsular space of the diabetic recipients. Recipient blood glucose and the survival time of the allografts were monitored. Antigen-specific mixed lymphocyte reaction was also evaluated.Results The recombinant lentiviral RNA interference vector OX40L-RNAi-LV reduced OX40L protein expression by 70%. The recombinant adenovirus vector Ad-PD-L1 increased PD-L1 protein expression in vivo in C57BL/6 recipient mice. Combined OX40L-RNAi-LV/Ad-PD-L1 treatment induced a synergistic protective effect in pancreatic islet allografts. Allograft survival time in the combined treatment group was (92.27+/-9.65) days, not only longer than that of the control ((6.51+/-0.27) days) and Ad-EGFP groups ((7.09+/-0.13) days) (P<0.01), but also significantly longer than that of Ad-PD-L1 and OX40L-RNAi-LV single treatment groups ((40.64+/-3.95) days and (55.14+/-5.48) days respectively, P<0.01). The blood glucose concentration of recipient mice in the combined treatment group was also stable and kept within the normal range. Flow cytometry analysis showed that combined OX40L-RNAi-LV/Ad-PD-L1 treatment significantly decreased proliferation in an antigen-specific mixed lymphocyte reaction. After donor DBA/2 lymphocyte stimulation, 89.71% of lymphocytes from recipient combination treatment C57BL/6 mice were not split and proliferated. In contrast, after stimulation with third party Lewis rat lymphocytes, only 45.84% lymphocytes of C57BL/6 mice were not split and proliferated.Conclusions This study demonstrates the successful construction of the recombinant lentivirus vector OX40L-RNAi-LV and adenovirus vector Ad-PD-L1 for the blockade of OX40/OX40L and activation of PD-1/PD-L1 costimulatory pathways simultaneously in pancreatic islet allografts in diabetic mice. Combination therapy with these two vectors resulted in inhibition of T cell activation, synergistically prolonging the survival time of pancreatic islet allografts.

Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice

Anti-CD25 mAb, Anti-IL2 mAb, and IL2 Block Tolerance Induction Through Anti-CD154 mAb and Rapamycin in Xenogeneic Islet Transplantation

Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection Via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice.

iPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation.

Adoptive Transfer with in Vitro Expanded Human Regulatory T Cells Protects Against Porcine Islet Xenograft Rejection Via Interleukin-10 in Humanized Mice

Enhancing human islet xenotransplant survival and function in diabetic immunocompetent mice through LRH-1/NR5A2 pharmacological activation

Mesenchymal Stem Cells in Combination with Low-Dose Rapamycin Significantly Prolong Islet Allograft Survival Through Induction of Regulatory T Cells.

A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models

Blockade of the OX40/OX40L Pathway and Induction of PD-L1 Synergistically Protects Mouse Islet Allografts from Rejection.

The study of long-term islet graft survival in C57BL/6(B6)mice treated with Tacrolimus, Rapamycin,and Anti-interleukin-2R antibody

Adoptive Transfer of Xenoantigen‑stimulated T Cell Receptor Vβ‑restricted Human Regulatory T Cells Prevents Porcine Islet Xenograft Rejection in Humanized Mice.

An immunosufficient murine model for the study of human islets.

Adoptive Infusion of Tolerogenic Dendritic Cells Prolongs the Survival of Pancreatic Islet Allografts: A Systematic Review of 13 Mouse and Rat Studies

IN VIVO ANTI-CD45RB ANTIBODY-INDUCED REGULATORY T CELLS DEMONSTRATE SPECIES-SPECIFIC TOLERANCE TO DISCORDANT HUMAN XENOGENIC ISLETS

Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells.

REGULATORY T CELLS MAINTAIN PERIPHERAL TOLERANCE TO ISLET ALLOGRAFTS INDUCED BY INTRATHYMIC INJECTION OF MHC CLASS I ALLOPEPTIDES

Liver NK1.1 cells and IL-22 promote pancreatic islets allograft survival in type 1 diabetic mice (TRAN2P.969)

Murine Islet Allograft Tolerance Upon Blockade of the B-Lymphocyte Stimulator, BLyS/BAFF

Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability

Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques

T Regulatory Cells to Prevent Autoimmune Diabetes and Promote Islet Allograft Survival in NOD Mice